These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31081606)

  • 1. When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation.
    Bagnasco D; Aloè T; Sclifò F; Ferrantino MG; Marugo F; Arcadipane F; Manfredi A; Canonica GW; Passalacqua G
    Eur Ann Allergy Clin Immunol; 2019 May; 51(3):135-137. PubMed ID: 31081606
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlling asthma. Highlights of the 1999 Canadian Asthma Consensus Report.
    D'Urzo AD
    Can Fam Physician; 2000 Apr; 46():895-8, 902-4. PubMed ID: 10790822
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.
    Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimӓki L
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1314-1316. PubMed ID: 32584603
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ACT score in mepolizumab discontinuation.
    Solanki N; Beck B; Labadia M; Smith K; Peterson L; King S; Micklewright S; Pennington E; Farooq S; Zhang P; Aronica M; Zein J; Khatri S; Comhair S; Erzurum S
    J Asthma; 2024 Jun; 61(6):550-560. PubMed ID: 38064231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 13. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients.
    Richards LB; van Bragt JJMH; Aarab R; Longo C; Neerincx AH; Sont JK; Weersink EJM; Braunstahl GJ; Brinke AT; Bel EHD; Maitland-van der Zee AH
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):2999-3008.e1. PubMed ID: 32344189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of mepolizumab for the treatment of asthma.
    Leung E; Al Efraij K; FitzGerald JM
    Expert Opin Drug Saf; 2017 Mar; 16(3):397-404. PubMed ID: 28116937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center.
    Voelker D; Almodallal Y; Scrodin MD; Lim K; Keogh K; Patel A; Iyer V
    Lung; 2020 Aug; 198(4):653-659. PubMed ID: 32583059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year of mepolizumab. Efficacy and safety in real-life in Italy.
    Bagnasco D; Caminati M; Menzella F; Milanese M; Rolla G; Lombardi C; Bucca C; Heffler E; Paoletti G; Testino E; Manfredi A; Caruso C; Guida G; Senna G; Bonavia M; Riccio AM; Canonica GW; Passalacqua G
    Pulm Pharmacol Ther; 2019 Oct; 58():101836. PubMed ID: 31473366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab (Nucala°) in asthma.
    Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.